On March 31, 2021, Applied Molecular Transport (AMT), a clinical-stage biopharmaceutical company leveraging its proprietary technology platform to design and develop a pipeline of novel biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases, announced the pricing of an underwritten public offering of 2,500,000 shares of its common stock at a public offering price of $42.00 per share. All of the shares of common stock are being offered by AMT. Wilson Sonsini Goodrich & Rosati is advising AMT on the transaction.
AMT has granted the underwriters a 30-day option to purchase up to an additional 375,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds to AMT from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by AMT, are expected to be $105 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on April 6, subject to the satisfaction of customary closing conditions.
The Wilson Sonsini team advising AMT on the transaction includes:
Corporate
Ken Clark
Tony Jeffries
Michael Coke
Christina Poulsen
Rachel Nagashima
Bartek Sudol
Zack Lenox
Marianne Stark Bradley
Patents and Innovations
Maya Skubatch
Rex Watkins
Jeff Seidel
Trisha Agrawal
Employee Benefits and Compensation
Brandon Gantus
Regulatory
David Hoffmeister
Eva Yin
Privacy and Cybersecurity
Matt Staples
Fintech
Amy Caiazza
Christine Liu
For more information, please see AMT’s press release.